David Langleben
- High prevalence of occult left heart disease in scleroderma-pulmonary hypertensionBy Benjamin D. Fox, Avi Shimony, David Langleben, Andrew Hirsch, Lawrence Rudski, Robert Schlesinger, Mark J. Eisenberg, Dominique Joyal, Marie Hudson, Kim Boutet, Alexandrina Serban, Ariel Masetto and Murray BaronBenjamin D. Fox1Center for Pulmonary Vascular Disease, Divisions of Cardiology, Respirology and Rheumatology, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal2Pulmonary Institute, Rabin Medical Center, Petach Tikva, IsraelAvi Shimony1Center for Pulmonary Vascular Disease, Divisions of Cardiology, Respirology and Rheumatology, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, MontrealDavid Langleben1Center for Pulmonary Vascular Disease, Divisions of Cardiology, Respirology and Rheumatology, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, MontrealAndrew Hirsch1Center for Pulmonary Vascular Disease, Divisions of Cardiology, Respirology and Rheumatology, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, MontrealLawrence Rudski1Center for Pulmonary Vascular Disease, Divisions of Cardiology, Respirology and Rheumatology, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, MontrealRobert Schlesinger1Center for Pulmonary Vascular Disease, Divisions of Cardiology, Respirology and Rheumatology, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, MontrealMark J. Eisenberg1Center for Pulmonary Vascular Disease, Divisions of Cardiology, Respirology and Rheumatology, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, MontrealDominique Joyal1Center for Pulmonary Vascular Disease, Divisions of Cardiology, Respirology and Rheumatology, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, MontrealMarie Hudson1Center for Pulmonary Vascular Disease, Divisions of Cardiology, Respirology and Rheumatology, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, MontrealKim Boutet3Division of Respirology, Hopital du Sacre Coeur, University of Montreal, MontrealAlexandrina Serban3Division of Respirology, Hopital du Sacre Coeur, University of Montreal, MontrealAriel Masetto4Division of Rheumatology, Centre Hospitalier Universite de Sherbrooke, Sherbrooke, QC, CanadaMurray Baron1Center for Pulmonary Vascular Disease, Divisions of Cardiology, Respirology and Rheumatology, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal
- EPITOME-2: Evaluation of a new formulation of epoprostenol sodium in pulmonary arterial hypertension patients switched from an originally approved formulationBy Olivier Sitbon, Marion Delcroix, Emmanuel Bergot, Anco Boonstra, Pilar Escribano Subias, Nazzareno Galiè, John Granton, David Langleben, Thomas Pfister, Jean-Christophe Lemarié and Gérald SimonneauOlivier Sitbon1Service de Pneumologie, Hôpital Universitaire de Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, FranceMarion Delcroix2Pneumology, Academic Hospital Gasthuisberg, Leuven, BelgiumEmmanuel Bergot3Service de Pneumologie, Hôpital Côte de Nacre-CHU, Caen, FranceAnco Boonstra4Pulmonology, VU University Medical Center, Amsterdam, NetherlandsPilar Escribano Subias5Servicio de Cardiología, Hospital Universitario 12 de Octubre, Madrid, SpainNazzareno Galiè6Institute of Cardiology, University of Bologna, ItalyJohn Granton7Pulmonary Hypertension Programme, Toronto General Hospital, Toronto, CanadaDavid Langleben8Jewish General Hospital, McGill University, Montreal, CanadaThomas Pfister9Global Medical Science, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandJean-Christophe Lemarié10Effi-Stat, Effi-stat, Paris, FranceGérald Simonneau1Service de Pneumologie, Hôpital Universitaire de Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, France
- Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT-1 studyBy Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi-Cheng Jing, Anne M. Keogh, David Langleben, Lewis J. Rubin, Michael Ochan Kilama, Arno Fritsch, Neil Davie and Hossein-Ardeschir GhofraniNazzareno Galiè1Institute of Cardiology, University of Bologna, Bologna, ItalyFriedrich Grimminger2Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center of Lung Research (DZL), Giessen, GermanyEkkehard Grünig3Centre for Pulmonary Hypertension at Thoraxclinic Heidelberg, Thoraxclinic at the University Hospital Heidelberg, Heidelberg, GermanyMarc Humbert4Univ. Paris-Sud; Inserm U999; AP-HP, Hôpital Bicêtre, Service De Pneumologie, Le Kremlin-Bicêtre, FranceZhi-Cheng Jing5Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, ChinaAnne M. Keogh6Heart Lung Transplant Unit, St Vincent's Hospital, Sydney, AustraliaDavid Langleben7Center for Pulmonary Vascular Disease, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, CanadaLewis J. Rubin8School of Medicine, University of California, San Diego, La Jolla, United StatesMichael Ochan Kilama9Global Clinical Development, Bayer HealthCare Pharmaceuticals, Milan, ItalyArno Fritsch10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyHossein-Ardeschir Ghofrani2Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center of Lung Research (DZL), Giessen, Germany
- Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 studyBy Ekkehard Grünig, Nazzareno Galiè, Marc Humbert, Anne M. Keogh, David Langleben, Lewis J. Rubin, Rudolf Speich, Arno Fritsch, Neil Davie and Hossein-Ardeschir GhofraniEkkehard Grünig1Centre for Pulmonary Hypertension at Thoraxclinic Heidelberg, Thoraxclinic at the University Hospital Heidelberg, Heidelberg, GermanyNazzareno Galiè2Institute of Cardiology, University of Bologna, Bologna, ItalyMarc Humbert3Univ. Paris-Sud; Inserm U999; AP-HP, Hôpital Bicêtre, Service De Pneumologie, Le Kremlin-Bicêtre, FranceAnne M. Keogh4Heart Lung Transplant Unit, St Vincent's Hospital, Sydney, AustraliaDavid Langleben5Center for Pulmonary Vascular Disease, Lady Davis Institute For Medical Research, Jewish General Hospital, McGill University, Montreal, CanadaLewis J. Rubin6School of Medicine, University of California, San Diego, La Jolla, United StatesRudolf Speich7Department of Internal Medicine, University Hospital Zurich, Zurich, SwitzerlandArno Fritsch8Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie8Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyHossein-Ardeschir Ghofrani9Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center of Lung Research (DZL), Giessen, Germany
- Impact of riociguat on health-related quality of life (HRQoL) in patients with pulmonary arterial hypertension (PAH)By Hossein-Ardeschir Ghofrani, Nazzareno Galiè, Friedrich Grimminger, Marc Humbert, Anne M. Keogh, Lewis J. Rubin, Mirko Sikirica, Arno Fritsch, Neil Davie, Stacie Hudgens, Nicola Bonner, Ba Luong and David LanglebenHossein-Ardeschir Ghofrani1Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center of Lung Research (DZL), Giessen, GermanyNazzareno Galiè2Institute of Cardiology, University of Bologna, Bologna, ItalyFriedrich Grimminger1Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center of Lung Research (DZL), Giessen, GermanyMarc Humbert3Univ. Paris-Sud, Inserm U999; AP-HP, Hôpital Bicêtre, Service De Pneumologie, Le Kremlin-Bicêtre, FranceAnne M. Keogh4Heart Lung Transplant Unit, St Vincent's Hospital, Sydney, AustraliaLewis J. Rubin5School of Medicine, University of California, San Diego, La Jolla, United StatesMirko Sikirica6Global HEOR, Bayer HealthCare Pharmaceuticals, Berlin, GermanyArno Fritsch7Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie7Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyStacie Hudgens8Healthcare Analytics, Adelphi Values US, Boston, United StatesNicola Bonner9Patient Reported Outcomes, Adelphi Values UK, Bollington, United KingdomBa Luong6Global HEOR, Bayer HealthCare Pharmaceuticals, Berlin, GermanyDavid Langleben10Center for Pulmonary Vascular Disease, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Canada
- High prevalence of occult left heart disease in scleroderma-pulmonary hypertensionBy Benjamin D Fox, Avi Shimony, David Langleben, Andrew Hirsch, Lawrence Rudski, Robert Schlesinger, Mark J Eisenberg, Dominique Joyal, Marie Hudson, Kim Boutet, Alexandrina Serban, Ariel Masetto and Murray BaronArticle | Published in 2012 in European Respiratory JournalBenjamin D Fox*Center for Pulmonary Vascular Disease, Divisions of Cardiology, Respirology and Rheumatology, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, Canada#Pulmonary Institute, Rabin Medical Center, Petach Tikva, IsraelAvi Shimony*Center for Pulmonary Vascular Disease, Divisions of Cardiology, Respirology and Rheumatology, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, CanadaDavid Langleben*Center for Pulmonary Vascular Disease, Divisions of Cardiology, Respirology and Rheumatology, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, CanadaAndrew Hirsch*Center for Pulmonary Vascular Disease, Divisions of Cardiology, Respirology and Rheumatology, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, CanadaLawrence Rudski*Center for Pulmonary Vascular Disease, Divisions of Cardiology, Respirology and Rheumatology, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, CanadaRobert Schlesinger*Center for Pulmonary Vascular Disease, Divisions of Cardiology, Respirology and Rheumatology, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, CanadaMark J Eisenberg*Center for Pulmonary Vascular Disease, Divisions of Cardiology, Respirology and Rheumatology, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, CanadaDominique Joyal*Center for Pulmonary Vascular Disease, Divisions of Cardiology, Respirology and Rheumatology, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, CanadaMarie Hudson*Center for Pulmonary Vascular Disease, Divisions of Cardiology, Respirology and Rheumatology, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, CanadaKim Boutet¶Division of Respirology, Hopital du Sacre Coeur, University of Montreal, Montreal, Quebec, CanadaAlexandrina Serban¶Division of Respirology, Hopital du Sacre Coeur, University of Montreal, Montreal, Quebec, CanadaAriel Masetto+Division of Rheumatology, Centre Hospitalier Universite de Sherbrooke, Sherbrooke, Quebec, CanadaMurray Baron*Center for Pulmonary Vascular Disease, Divisions of Cardiology, Respirology and Rheumatology, and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
- Late-breaking abstract: Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extensionBy Lewis J. Rubin, Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi-Cheng Jing, Anne Keogh, David Langleben, Arno Fritsch, Flavia Menezes, Neil Davie and Hossein-Ardeschir GhofraniLewis J. Rubin1School of Medicine, University of California, San Diego, La Jolla,Nazzareno Galiè2Dept of Experimental, Diagnostic and Specialty Medicine–DIMES, Bologna University Hospital, Bologna, ItalyFriedrich Grimminger3Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), member of the German Center of Lung Research (DZL), Giessen, GermanyEkkehard Grünig4Centre for Pulmonary Hypertension at the Thoraxclinic, University Hospital Heidelberg, Heidelberg, GermanyMarc Humbert5Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin–Bicêtre, FranceZhi-Cheng Jing6State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, ChinaAnne Keogh7Cardiac Transplant, St Vincent's Hospital, Sydney, AustraliaDavid Langleben8Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, CanadaArno Fritsch9Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyFlavia Menezes10Clinical Development, Bayer HealthCare Pharmaceuticals, São Paulo, BrazilNeil Davie9Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyHossein-Ardeschir Ghofrani3Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), member of the German Center of Lung Research (DZL), Giessen, Germany11Dept of Medicine, Imperial College London, London, United Kingdom
- Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)By Lewis J. Rubin, Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi-Cheng Jing, Anne Keogh, David Langleben, Arno Fritsch, Flavia Menezes, Neil Davie and Hossein-Ardeschir GhofraniArticle | Published in 2015 in European Respiratory JournalLewis J. Rubin1Dept of Medicine, University of California, San Diego, La Jolla, California, USANazzareno Galiè2Dept of Experimental, Diagnostic and Specialty Medicine–DIMES, Bologna University Hospital, Bologna, ItalyFriedrich Grimminger3University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany4Member of the German Center of Lung Research (DZL)Ekkehard Grünig5Centre for Pulmonary Hypertension, Thoraxclinic, University Hospital Heidelberg, Heidelberg, GermanyMarc Humbert6Université Paris-Sud, Le Kremlin-Bicêtre, France7AP-HP Service de Pneumologie, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France8INSERM U999, LabEx LERMIT, Centre Chirurgical Marie Lannelongue, Le Plessis, Robinson, FranceZhi-Cheng Jing9State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, ChinaAnne Keogh10St Vincent's Hospital, Sydney, AustraliaDavid Langleben11Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, CanadaArno Fritsch12Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyFlavia Menezes13Bayer HealthCare Pharmaceuticals, São Paulo, BrazilNeil Davie12Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyHossein-Ardeschir Ghofrani3University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany4Member of the German Center of Lung Research (DZL)14Dept of Medicine, Imperial College London, London, UK
- Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)By Lewis J. Rubin, Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi-Cheng Jing, Anne Keogh, David Langleben, Arno Fritsch, Flavia Menezes, Neil Davie and Hossein-Ardeschir GhofraniLewis J. Rubin1Dept of Medicine, University of California, San Diego, La Jolla, California, USANazzareno Galiè2Dept of Experimental, Diagnostic and Specialty Medicine–DIMES, Bologna University Hospital, Bologna, ItalyFriedrich Grimminger3University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany4Member of the German Center of Lung Research (DZL)Ekkehard Grünig5Centre for Pulmonary Hypertension, Thoraxclinic, University Hospital Heidelberg, Heidelberg, GermanyMarc Humbert6Université Paris-Sud, Le Kremlin-Bicêtre, France7AP-HP Service de Pneumologie, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France8INSERM U999, LabEx LERMIT, Centre Chirurgical Marie Lannelongue, Le Plessis, Robinson, FranceZhi-Cheng Jing9State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, ChinaAnne Keogh10St Vincent's Hospital, Sydney, AustraliaDavid Langleben11Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, CanadaArno Fritsch12Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyFlavia Menezes13Bayer HealthCare Pharmaceuticals, São Paulo, BrazilNeil Davie12Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyHossein-Ardeschir Ghofrani3University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany4Member of the German Center of Lung Research (DZL)14Dept of Medicine, Imperial College London, London, UK
- Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i)By Marius Hoeper, Raymond Benza, Gerald Simonneau, James Klinger, David Langleben, Robert Naeije and Paul CorrisMarius Hoeper1Clinic for Respiratory Medicine, Hannover Medical School, Hannover, GermanyRaymond Benza2Gerald McGinnis Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, United StatesGerald Simonneau3Pneumology and ICU, Bicetre Hospital, Paris-Sud University, Paris, FranceJames Klinger4Respiratory Care Unit, Rhode Island Hospital, Providence, RI United StatesDavid Langleben5Center for Pulmonary Vascular Disease, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC CanadaRobert Naeije6Department of Cardiology, Erasme University Hospital, Brussels, BelgiumPaul Corris7Thoracic Medicine, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom
- Calculation of REVEAL scores for patients with PAH receiving riociguat in the PATENT-2 studyBy Raymond Benza, Adaani Frost, Harrison Farber, Hossein-Ardeschir Ghofrani, Miguel Angel Gómez Sánchez, David Langleben, Stephan Rosenkranz, Dennis Busse, Christian Meier, Sylvia Nikkho and Marius HoeperRaymond Benza1Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA United StatesAdaani Frost2Baylor College of Medicine, Division of Cardiovascular Diseases, Houston, TX United StatesHarrison Farber3Pulmonary Center, Boston University School of Medicine, Boston, MA United StatesHossein-Ardeschir Ghofrani4Member of the German Center of Lung Research (DZL), University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany5Department of Medicine, Imperial College London, London, United KingdomMiguel Angel Gómez Sánchez6Cardiology Service, Hospital Universitario 12 de Octubre, Madrid, SpainDavid Langleben7Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, CanadaStephan Rosenkranz8Department of Cardiology, Heart Center, University Hospital of Cologne, Cologne, GermanyDennis Busse9Global Data Sciences and Analytics, Chrestos Concept GmbH & Co. KG, Ratingen, GermanyChristian Meier10Global Clinical Development, Bayer Pharma AG, Berlin, GermanySylvia Nikkho10Global Clinical Development, Bayer Pharma AG, Berlin, GermanyMarius Hoeper11Member of the German Center of Lung Research (DZL), Clinic for Respiratory Medicine, Hannover Medical School, Hannover, Germany
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.